Limonoid 7-Deacetoxy-7-oxogedunin (CG-1) Attenuates RANKL-Induced Osteoclastogenesis via Inhibiting PI3K/Akt-NFATc1 Axis
Cells · 07.05.2026 · 15 (10) · 854
DOI: 10.3390/cells15100854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 07.05.2026. Verfasst von Atsushi Koike und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan. Hauptthemen laut MEDLINE: RANK Ligand, NFATC Transcription Factors, Limonins, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Excessive bone resorption by osteoclasts causes pathological bone loss in diseases such as osteoporosis. 7-Deacetoxy-7-oxogedunin (CG-1), a limonoid isolated from Carapa guianensis (Meliaceae), exhibits various biological activities. Here, we examined the anti-osteoclastogenic effect of CG-1 and its underlying mechanism in receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. CG-1 inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated cells and decreased the expression of osteoclastogenesis-related genes. When CG-1 was added to the culture during the first 3 days of the 5-day-osteoclastogenesis period, the expression levels of the osteoclastogenesis-related genes (Nfatc1, Acp5, Src, Ctsk, and Mmp9) were decreased, as was observed when CG-1 was added continuously for 5 days. Furthermore, CG-1 lowered RANKL-induced Akt phosphorylation, which is similar to the results seen with the PI3K inhibitor, LY294002. Moreover, CG-1 and LY294002 suppressed the RANKL-induced expression of NFATc1, the master transcription factor for regulating terminal differentiation into osteoclasts. These results suggest that CG-1 attenuated RANKL-induced osteoclastogenesis by inhibiting the PI3K/Akt-NFATc1 axis during the early stage of osteoclast differentiation. Thus, CG-1 has the potential to suppress osteoclast-mediated bone resorption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan.
ORCID-Profile: Ko Fujimori
Zitieren
APA
Koike, A., & Fujimori, K. (2026). Limonoid 7-Deacetoxy-7-oxogedunin (CG-1) Attenuates RANKL-Induced Osteoclastogenesis via Inhibiting PI3K/Akt-NFATc1 Axis. Cells, 15(10), 854. https://doi.org/10.3390/cells15100854
Vancouver
Koike A, Fujimori K. Limonoid 7-Deacetoxy-7-oxogedunin (CG-1) Attenuates RANKL-Induced Osteoclastogenesis via Inhibiting PI3K/Akt-NFATc1 Axis. Cells. 2026;15(10):854. doi:10.3390/cells15100854
BibTeX
@article{Koike2026,
author = {Koike, Atsushi and Fujimori, Ko},
title = {Limonoid 7-Deacetoxy-7-oxogedunin (CG-1) Attenuates RANKL-Induced Osteoclastogenesis via Inhibiting PI3K/Akt-NFATc1 Axis},
journal = {Cells},
year = {2026},
volume = {15},
number = {10},
pages = {854},
doi = {10.3390/cells15100854}
}
EUVIMED